Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
42,194,093
-
Total 13F shares
-
43,564,795
-
Share change
-
+3,098,029
-
Total reported value
-
$2,238,109,529
-
Put/Call ratio
-
38%
-
Price per share
-
$51.37
-
Number of holders
-
191
-
Value change
-
+$155,550,094
-
Number of buys
-
98
-
Number of sells
-
105
Institutional Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) as of Q1 2025
As of 31 Mar 2025 Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) had 191 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 43,564,795 shares of stock of the company.
Largest 10 holders included RTW INVESTMENTS, LP, BlackRock, Inc., Paradigm Biocapital Advisors LP, JENNISON ASSOCIATES LLC, TANG CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, MORGAN STANLEY, TORONTO DOMINION BANK, Deep Track Capital, LP, and Frazier Life Sciences Management, L.P..
This table shows 192 institutional shareholders of the security as of 31 Mar 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.